Busulfan or TBI: answer to an age-old question

Area of Science:

• Hematology
• Oncology
• Transplantation Medicine

Background:

• Acute myeloid leukemia (AML) is a significant hematologic malignancy.
• Hematopoietic stem cell transplantation (HSCT) is a curative option for AML.
• Preparative regimens are crucial for HSCT success, aiming to eradicate leukemia and prevent graft-versus-host disease.

Purpose of the Study:

• To compare the efficacy and safety of busulfan versus total body irradiation (TBI) in preparative regimens for AML patients undergoing HSCT.
• To provide evidence-based guidance for selecting optimal conditioning agents in AML treatment protocols.

Main Methods:

• Analysis of two independent studies evaluating busulfan-based versus TBI-based preparative regimens.
• Comparison of patient outcomes including leukemia relapse rates, overall survival, and treatment-related toxicity.
• Assessment of conditioning regimen intensity and its impact on engraftment and graft-versus-host disease.

Main Results:

• Busulfan and TBI demonstrate comparable efficacy in terms of leukemia control and survival.
• Differences in toxicity profiles and long-term complications may exist between the two regimens.
• Specific patient subgroups might benefit more from one regimen over the other, warranting further investigation.

Conclusions:

• Both busulfan and TBI are viable options for preparative regimens in AML HSCT.
• Regimen selection should be individualized based on patient characteristics, disease status, and institutional expertise.
• Further research is needed to refine conditioning strategies and minimize treatment-related morbidity in AML patients.